Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDennis Ding - AnalystDev Prasad - SVP, Biotech Equity Research AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Anal ...

Core Viewpoint - Cumberland Pharmaceuticals Inc. experienced a significant decline in stock price despite reporting strong revenue growth for the fourth quarter of 2025, indicating potential market concerns despite operational improvements [1][2]. Financial Performance - For Q4 2025, Cumberland reported net revenues of $13.7 million, a 31% increase year-over-year, equating to a $3.2 million improvement [2]. - Operating expenses rose to $15 million from $12 million in the previous year, leading to a net loss of $1.41 million, an improvement from a net loss of $1.90 million in the prior year [3]. - Total net revenues for 2025 reached $44.5 million, an 18% increase year-over-year, meeting management's goal for double-digit growth [4]. - Adjusted earnings for the year were $1.7 million, a $2.7 million improvement from 2024, with cash flow from operations totaling $4.9 million, up $5.5 million from the previous year [5]. Balance Sheet and Financial Position - At the end of 2025, Cumberland had total assets of $76.8 million, including $11.4 million in cash, total liabilities of $52.3 million, and shareholders' equity of $24.9 million [6]. - The company reduced its credit facility balance by over $10 million during the year, enhancing its financial stability [6]. Management Insights - CEO A.J. Kazimi described 2025 as a strong year, emphasizing revenue growth and portfolio expansion driven by increased demand for marketed brands like Vibativ and Sancuso [7]. - Management highlighted progress in the company's pipeline and global expansion strategy, including strengthening the commercial organization and expanding international partnerships [8]. Product Performance and Market Dynamics - Key products contributing to revenue growth included Kristalose, Sancuso, Vibativ, Caldolor, and Talicia, with Talicia beginning to generate sales in Q4 [2][4][9]. - The revenue increase was accompanied by higher operating expenses due to increased royalties and costs associated with higher sales volumes [10]. - Kristalose faced challenges from growing generic competition, which management acknowledged as a continuing issue [11]. Strategic Initiatives - Cumberland entered a co-commercialization agreement with RedHill Biopharma for Talicia, sharing net revenues while handling distribution and sales [12]. - The company made strides in international expansion, securing regulatory approvals for Vibativ in China and injectable ibuprofen in Mexico, and launching Vibativ in Saudi Arabia [13]. - A permanent reimbursement J-code for Caldolor was established by the Centers for Medicare & Medicaid Services, potentially supporting broader adoption in hospitals [14]. Clinical Development - Cumberland reported positive clinical progress for its pipeline candidate ifetroban, with the Phase II FIGHT DMD study showing encouraging results and receiving FDA Fast Track designation [15].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [10][11] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% of revenue) in the prior year [10][11] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [11][12] - Net loss for 2025 was $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.03 per share) in 2024 [12][13] - Adjusted EBITDA loss for 2025 was $20.3 million, compared to a loss of $14.8 million in 2024 [13] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10][11] - SG&A expenses totaled $3.6 million in Q4 2025, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [11] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold [8][9] Market Data and Key Metrics Changes - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's approximately 90 target accounts [9] - Recent data from the Israel Defense Forces indicated that NexoBrid was clinically applicable in 71% of war-related injuries, supporting its role in acute trauma care [9] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded facility [16] - MediWound has reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges while focusing on clinical milestones and commercial objectives [5] - The company anticipates a significant increase in revenues in the second half of 2026, driven by manufacturing capacity and BARDA revenue [83] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [14][15] - The company is expanding its clinical program for EscharEx beyond venous leg ulcers to include diabetic foot ulcers and pressure ulcers, with studies expected to begin in the second half of 2026 [7][8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - Management indicated that the expanded manufacturing facility is operational, with regulatory approvals expected in late 2026, and demand is larger than current manufacturing capacity [19][20] Question: Can you discuss the pressure ulcer trial and its potential market size? - Management noted that pressure ulcers are considered a significant market opportunity, and a third-party market research project will help assess the size of the addressable market [27][28] Question: What is the status of BARDA and DoD support for revenue guidance? - Management confirmed that revenue guidance includes potential contributions from BARDA and the DoD, with ongoing discussions expected to resume following the normalization of federal operations [33][34] Question: How is the supply chain for clinical studies being managed amid geopolitical tensions? - Management assured that there is sufficient EscharEx supply to support the trial for at least six months, with no anticipated supply chain issues impacting the clinical study [46] Question: What is the expected impact of the interim analysis on the VALUE trial timeline? - Management stated that the interim analysis will be conducted after 65% enrollment, with potential adjustments to sample size if necessary, which could impact the timeline [44]

UroGen Pharma FY Conference Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Industry**: Biotechnology, specifically focused on bladder cancer treatments Key Highlights - **Transformational Year**: UroGen is experiencing a pivotal year with the approval of JELMYTO for bladder cancer, marking a significant milestone since the company's inception [10][11] - **Financial Position**: The company has successfully completed debt refinancing, enhancing its financial stability and flexibility for future growth [60][61] - **Product Launch**: JELMYTO's launch is unique as it involves a procedure rather than a traditional pill or infusion, impacting the treatment timeline for patients [16][17] Financial Performance - **Q4 Results**: UroGen reported Q4 revenues of approximately $14 million, with $4.5 million generated in October alone, indicating strong initial uptake [19] - **Growth Expectations**: The company anticipates accelerated growth following the introduction of a permanent J-code, which is crucial for reimbursement confidence among physicians [17][20] Market Dynamics - **Patient Enrollment**: About 80% to 90% of patients are processed through a hub that manages patient enrollment forms, which are critical for tracking demand [23][25] - **Conversion Rates**: The conversion rate from patient enrollment forms to actual treatments is currently around 70%-80%, with efforts to reduce the time from enrollment to treatment [31][25] Competitive Landscape - **Unique Positioning**: UroGen is the only company offering a treatment for low-grade non-muscle invasive bladder cancer, differentiating itself from competitors [18] - **Market Potential**: The bladder cancer market is estimated to be a $5 billion opportunity, with UroGen aiming to capture a significant share through its innovative treatments [35][36] Pipeline Developments - **UGN-103**: This next-generation formulation is expected to have patent protection until 2042, with clinical data anticipated mid-year [66] - **UGN-501**: An oncolytic virus with potential applications beyond bladder cancer, currently in early development stages [70][71] Strategic Vision - **Long-term Growth**: UroGen aims to build a sustainable growth company by leveraging its unique product offerings and expanding its market presence [10][12] - **Focus on Education**: The company is committed to educating physicians on the benefits of its treatments to drive adoption and increase patient access [35][46] Undervalued Aspects - **Market Valuation**: The CEO highlighted that the market valuation does not fully reflect the potential of ZUSDURI, which could represent a $1.2 billion opportunity if the company captures 20% of the patient population [76] Conclusion - UroGen Pharma is positioned for significant growth in the bladder cancer treatment market, with a strong financial foundation, innovative products, and a strategic focus on education and market penetration. The upcoming quarters will be critical in determining the trajectory of its growth and market acceptance.

Core Viewpoint - Helus Pharma has appointed Michael Cola as CEO to lead the company through pivotal clinical milestones in its mental health therapy pipeline, focusing on novel serotonergic agonists [2][3][4]. Company Overview - Helus Pharma, a clinical stage pharmaceutical company, is dedicated to developing novel serotonergic agonists aimed at treating mental health disorders such as depression and anxiety [8][9]. - The company has filed over 350 patent applications globally and holds more than 100 granted patents, indicating a strong intellectual property position [3]. Leadership Appointment - Michael Cola's appointment as CEO is seen as crucial for advancing Helus's pipeline, particularly with upcoming Phase 2 data for HLP004 and Phase 3 topline data for HLP003 [3][6]. - Cola has over 30 years of experience in neuroscience and pharmaceuticals, having previously led significant growth initiatives at Shire and other companies [4][5]. Clinical Development - Helus is advancing HLP003, which is in Phase 3 for major depressive disorder and has received Breakthrough Therapy Designation from the FDA, and HLP004, currently in Phase 2 for generalized anxiety disorder [9]. - The company aims to improve treatment outcomes for serious mental health disorders through its differentiated pipeline of NSAs [9]. Market Position and Strategy - The company is focused on global regulatory engagement and long-term commercial planning as it transitions from early clinical development to later-stage execution [3]. - Cola's leadership is expected to enhance the company's ability to translate scientific advancements into effective therapies and shareholder value [4][5].

Core Viewpoint - Altimmune Inc has announced a $75 million registered direct offering of common stock, leading to a significant decline in its share price [1][9]. Group 1: Offering Details - The company has entered a securities purchase agreement for the sale of 17,045,454 shares of common stock, or pre-funded warrants [2]. - The offering is expected to generate approximately $75 million in gross proceeds, priced at about $4.40 per share, and is anticipated to close around January 29, subject to customary conditions [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to fund preparations for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [4]. Group 3: Stock Performance - Currently, Altimmune's stock is trading 17.4% above its 20-day simple moving average and 19.8% above its 100-day simple moving average, indicating short-term strength despite the recent decline [5]. - Over the past 12 months, shares have decreased by approximately 26.33% and are closer to their 52-week lows than highs [5]. - The stock's RSI is at 78.59, indicating overbought territory, while the MACD shows bullish momentum, suggesting a potential correction may be due [6]. Group 4: Company Overview - Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases, with its product candidate pemvidutide being a dual receptor agonist currently in clinical development [7]. - The recent stock offering is significant as it aims to fund further development of pemvidutide, which could address major health issues [8].

Summary of Roivant Sciences FY Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: FY Conference Call on January 12, 2026 - **Speaker**: CEO Matt Gline Key Points Company Positioning and Strategy - Roivant is entering a new era with a significantly simplified business model focused on a smaller subset of products, emphasizing clinical execution and pipeline potential [3][4] - The company aims to shape its own destiny with a high priority on delivering results from its clinical programs [3] Financial Strength - Roivant reported a cash balance of **$4.4 billion**, positioning it well for future growth without the need for additional fundraising [5][9] - The company has a strong track record with **12 positive phase III studies** and **8 FDA approvals**, indicating robust past performance and a solid pipeline [9] Clinical Development Highlights - **Brepocitinib**: Positive data for dermatomyositis (DM) with plans to file an NDA by early 2026, marking it as the first novel oral therapeutic for DM [4][5] - **IMVT-1402**: Progressing in pivotal studies for Graves' disease, with expectations for significant disease-modifying benefits [4] - Upcoming data releases include registrational programs for brepocitinib in non-infectious uveitis (NIU) and phase IIb data for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) [6][7] Market Opportunities - The company sees a potential **$15 billion-plus portfolio** across various indications, with significant opportunities in DM, NIU, and Graves' disease [19][70] - Brepocitinib is expected to capture market share from existing therapies, particularly for patients currently on high-dose steroids or IVIG [41][42] Competitive Landscape - Roivant is positioned to be among the first non-prostacyclin novel mechanisms in PH-ILD, competing against established treatments [6][57] - The company is optimistic about the potential for brepocitinib to outperform existing treatments in DM, especially given the enthusiasm from physicians [41][46] Legal and Regulatory Environment - Ongoing litigation with Moderna regarding lipid nanoparticle technology, with a jury trial scheduled for March 2026 [5][60] - The outcome of this case may have implications for other ongoing litigations and the company's overall strategy [62] Future Outlook - Roivant anticipates a transformative next 36 months with multiple commercial launches and pivotal study readouts [11][19] - The company is focused on executing its clinical programs and expanding its pipeline to drive future value [19][29] Unique Business Model - Roivant's model combines talent from various backgrounds, emphasizing creative clinical development and a focus on delivering value to patients [10][30] - The company aims to differentiate itself by maintaining high standards for partnerships and transactions, driven by a focus on profitability [36] Conclusion - Roivant Sciences is positioned for significant growth with a strong financial foundation, a focused pipeline, and a commitment to innovative clinical development. The upcoming years are expected to be pivotal for the company as it seeks to capitalize on its opportunities in the biotech space [19][70]

As filed with the Securities and Exchange Commission on December 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 82-4369909 (I.R.S. Employer Identification Number) (State or other jurisdiction of incorporation or organization) 2223 Avenida de la Playa, ...

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]

Core Insights - The company has transitioned from being primarily a diabetes-focused entity to diversifying its portfolio, particularly in the area of rare diseases and orphan lung conditions [1] - The partnership with UT has been fruitful and continues to develop positively, indicating a strong collaborative effort in research and development [1] - The company aims to create more catalysts for growth and positive developments to attract momentum and catalyst-driven investors [1]